drugset
drugset / Trial / NCT06799039

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

NCT06799039 ↗

Phase 0 Not yet recruiting 69 enrolled Brigham and Women's Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.

Timeline

Start
2026-09-01
Primary completion
2030-09-01
Completion
2031-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Xylitol Small molecule 1 g Oral
Subject Xylitol Small molecule 2 g Oral
Subject Xylitol Small molecule 5 g Oral
Subject Xylitol Small molecule 7 g Oral
Subject Xylitol Small molecule 9 g Oral

Indications

Clostridium difficile colitis